GlassScriptPhysician profile
Daniel G Muldoon
NPI 1154384089
$1,665.66
in general payments reported to CMS, 2019-2025
27 companies · $617 in 2025
The $617 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $134 · 2021: $218 · 2022: $131 · 2023: $76.30 · 2024: $489 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160 · Entertainment: $22.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.96 |
| Entertainment | $22.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $312.07 | 2021-2025 | |
| Novo Nordisk INC | $241.94 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $124.27 | 2023-2025 | Veozah |
| Horizon Therapeutics Plc | $116.16 | 2021-2023 | |
| Pfizer INC. | $83.28 | 2020-2024 | |
| Lilly USA, LLC | $65.19 | 2025 | Zepbound, Mounjaro |
| Allergan, INC. | $62.82 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $54.17 | 2021-2024 | Farxiga, Breztri |
| E.R. Squibb & Sons, L.L.C. | $54.14 | 2020-2025 | Eliquis |
| Exact Sciences Corporation | $51.31 | 2024-2025 | Cologuard Collection Kit |
| Exeltis, USA INC. | $48.06 | 2024-2025 | Slynd |
| Abbott Laboratories | $47.86 | 2024-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $45.93 | 2024-2025 | Myfembree, Gemtesa |
| Amgen INC. | $43.67 | 2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $40.83 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.98 | 2020-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $34.57 | 2022-2025 | Rexulti |
| Coopersurgical, INC. | $34.33 | 2024 | Wallach Cryosurgical Equipment |
| Optumhealth Care Solutions, LLC | $25.19 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Organon LLC | $23.33 | 2025 | Nexplanon, Nuvaring |
| Provepharm INC. | $22.64 | 2024 | Bludigo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.49 | 2024 | Xifaxan |
| Boston Scientific Corporation | $17.89 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.47 | 2021 | |
| Currax Pharmaceuticals LLC | $13.69 | 2024 | Contrave |
| Acadia Pharmaceuticals INC | $13.33 | 2024 | Nuplazid |
| Glaxosmithkline, LLC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Muldoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.